72 related articles for article (PubMed ID: 2959047)
1. Thromboxane biosynthesis and antagonism in humans.
FitzGerald GA; Fitzgerald DJ; Lawson JA; Murray R
Adv Prostaglandin Thromboxane Leukot Res; 1987; 17A():199-203. PubMed ID: 2959047
[TBL] [Abstract][Full Text] [Related]
2. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
Vezza R; Nenci GG; Gresele P
J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
[TBL] [Abstract][Full Text] [Related]
3. [Thromboxane antagonism in thrombocytes--pathophysiology, pharmacology and possible clinical significance].
Schrör K
Wien Klin Wochenschr; 1991; 103(18):543-53. PubMed ID: 1836294
[TBL] [Abstract][Full Text] [Related]
4. Thromboxane A2 biosynthesis in human disease.
FitzGerald GA; Healy C; Daugherty J
Fed Proc; 1987 Jan; 46(1):154-8. PubMed ID: 3100340
[TBL] [Abstract][Full Text] [Related]
5. Overview of physiological and pathophysiological effects of thromboxane A2.
Ogletree ML
Fed Proc; 1987 Jan; 46(1):133-8. PubMed ID: 2948837
[TBL] [Abstract][Full Text] [Related]
6. Thromboxane A2 in cardiovascular and renal disorders: is there a defined role for thromboxane receptor antagonists or thromboxane synthase inhibitors?
Smith EF
Eicosanoids; 1989; 2(4):199-212. PubMed ID: 2534279
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
[TBL] [Abstract][Full Text] [Related]
8. [Thromboxane A2 and prevention of cardiovascular diseases].
Schrör K
Z Kardiol; 1992; 81 Suppl 4():185-9. PubMed ID: 1290297
[TBL] [Abstract][Full Text] [Related]
9. Biochemical and pharmacological evaluation of thromboxane synthetase inhibitors.
Gorman RR
Adv Prostaglandin Thromboxane Res; 1980; 6():417-25. PubMed ID: 6247892
[No Abstract] [Full Text] [Related]
10. Binding of a thromboxane A2/prostaglandin H2 receptor antagonist to washed human platelets.
Mais DE; Burch RM; Saussy DL; Kochel PJ; Halushka PV
J Pharmacol Exp Ther; 1985 Dec; 235(3):729-34. PubMed ID: 3001275
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic characterization of human and canine thromboxane A2/prostaglandin H2 receptors in platelets and blood vessels: evidence for different receptors.
Mais DE; Saussy DL; Chaikhouni A; Kochel PJ; Knapp DR; Hamanaka N; Halushka PV
J Pharmacol Exp Ther; 1985 May; 233(2):418-24. PubMed ID: 2987481
[TBL] [Abstract][Full Text] [Related]
12. A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis.
Salvati P; Dho L; Ukmar G; Vaga L; Rimoldi O; Patrono C
J Pharmacol Exp Ther; 1994 Apr; 269(1):238-45. PubMed ID: 8169831
[TBL] [Abstract][Full Text] [Related]
13. Binding of an 125I-labeled thromboxane A2/prostaglandin H2 receptor antagonist to washed canine platelets.
Mais DE; Kochel PJ; Saussy DL; Halushka PV
Mol Pharmacol; 1985 Aug; 28(2):163-9. PubMed ID: 2991736
[TBL] [Abstract][Full Text] [Related]
14. Antivasoconstrictor and antiaggregatory activities of picotamide unrelated to thromboxane A2 antagonism.
Vezza R; Spina D; Tallarida RJ; Nathan M; Page CP; Gresele P
Thromb Haemost; 1997 Nov; 78(5):1385-91. PubMed ID: 9408024
[TBL] [Abstract][Full Text] [Related]
15. Thromboxane biosynthesis in cardiovascular diseases.
Patrono C; Ciabattoni G; Davi G
Stroke; 1990 Dec; 21(12 Suppl):IV130-3. PubMed ID: 2260137
[TBL] [Abstract][Full Text] [Related]
16. An antithrombotic agent, NQ301, inhibits thromboxane A2 receptor and synthase activity in rabbit platelets.
Jin YR; Cho MR; Lee KS; Lee JJ; Lim Y; Han XH; Oh KW; Hong JT; Yoo HS; Yun YP
Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):162-7. PubMed ID: 16128910
[TBL] [Abstract][Full Text] [Related]
17. Thromboxane synthesis inhibitors and receptor antagonists.
Patrono C
Thromb Res Suppl; 1990; 11():15-23. PubMed ID: 2148990
[TBL] [Abstract][Full Text] [Related]
18. 2-(2-Br-phenyl)-8-methoxy-benzoxazinone (HPW-RX2), a direct thrombin inhibitor with a suppressive effect on thromboxane formation in platelets.
Wu CC; Wang TW; Wang WY; Hsieh PW; Wu YC
Eur J Pharmacol; 2005 Dec; 527(1-3):37-43. PubMed ID: 16313903
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist.
Hanson J; Rolin S; Reynaud D; Qiao N; Kelley LP; Reid HM; Valentin F; Tippins J; Kinsella BT; Masereel B; Pace-Asciak C; Pirotte B; Dogné JM
J Pharmacol Exp Ther; 2005 Apr; 313(1):293-301. PubMed ID: 15626721
[TBL] [Abstract][Full Text] [Related]
20. Antiplatelet effect of a new inhibitor of thromboxane synthase and thromboxane A2 receptors.
Tubaro E; Belogi L; Mezzadri CM
Arzneimittelforschung; 1996 Jan; 46(1):35-41. PubMed ID: 8821515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]